Association between metabolic syndrome and rate of lung function decline: A longitudinal analysis

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 11, 2013, Pages 1507-1514

  Koo, H K ^a   Kim, D K ^b   Chung, H S ^b   Lee, Chang Hoon ^c  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

Author keywords

Acceleration; Anti hypertensive medication; Metabolic syndrome

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERTENSION; LONGITUDINAL STUDY; LUNG FUNCTION; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; QUESTIONNAIRE; RESPIRATORY TRACT DISEASE; SMOKING; SPIROMETRY; WAIST CIRCUMFERENCE;

ADULT; ANTIHYPERTENSIVE AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERTENSION; LINEAR MODELS; LONGITUDINAL STUDIES; LUNG; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK FACTORS; SPIROMETRY; TIME FACTORS; VITAL CAPACITY;

EID: 84888107273     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0906     Document Type: Article

References (34)

1. Janssens J P, Pache J C, Nicod L P. Physiological changes in respiratory function associated with ageing. Eur Respir J 1999; 13: 197-205. (Pubitemid 29079244)
2. Roisin R R. Global strategy for the diagnosis, management and prevention of COPD. Updated 2011. Bethesda, MD, USA: GOLD, 2011. http://www.goldcopd.org/ uploads/users/files/GOLD-Report-2011-Feb21.pdf Accessed September 2013.
3. Ito K, Barnes P J. COPD as a disease of accelerated lung aging. Chest 2009; 135: 173-180.
4. Mohamed Hoesein F A, van Rikxoort E, van Ginneken B, et al. Computed tomography-quantified emphysema distribution is associated with lung function decline. Eur Respir J 2012; 40: 844-850.
5. Scanlon P D, Connett J E, Waller L A, Altose M D, Bailey W C, Buist A S. Smoking cessation and lung function in mild-tomoderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381-390. (Pubitemid 30129442)
6. Donaldson G C, Seemungal T A, Bhowmik A, Wedzicha J A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852. (Pubitemid 35178607)
7. Walter R E, Beiser A, Givelber R J, O'Connor G T, Gottlieb D J. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003; 167: 911-916. (Pubitemid 36801781)
8. Leone N, Courbon D, Thomas F, et al. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. Am J Respir Crit Care Med 2009; 179: 509-516.
9. Yeh F, Dixon A E, Marion S, et al. Obesity in adults is associated with reduced lung function in metabolic syndrome and diabetes: the Strong Heart Study. Diabetes Care 2011; 34: 2306-2313.
10. Kim H J, Lee J Y, Jung H S, et al. The impact of insulin sensitisers on lung function in patients with chronic obstructive pulmonary disease and diabetes. Int J Tuberc Lung Dis 2010; 14: 362-367.
11. Schnabel E, Nowak D, Brasche S, Wichmann H E, Heinrich J. Association between lung function, hypertension and blood pressure medication. Respir Med 2011; 105: 727-733.
12. Miller M R, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-338. (Pubitemid 41079078)
13. Morris J F, Koski A, Johnson L C. Spirometric standards for healthy non-smoking adults. Am Rev Respir Dis 1971; 103: 57-67.
14. Lee C H, Lee J Y, Jang E J, Park K Y, Han H W. New predictive equations for spirometric reference values and comparison with Morris equation in a Korean population. Respirology 2008; 13: 365-371.
15. Celli B R, Thomas N E, Anderson J A, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178: 332-338.
16. Grundy S M, Cleeman J I, Daniels S R, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752. (Pubitemid 41532612)
17. Tashkin D P, Celli B, Senn S, et al. UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359: 1543-1554.
18. Pauwels R A, Löfdahl C G, Laitinen L A, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953. (Pubitemid 29288270)
19. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 1902-1909.
20. Burge P S, Calverley P M, Jones P W, Spencer S, Anderson J A, Maslen T K. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303. (Pubitemid 30245717)
21. Yeh H C, Punjabi N M, Wang N Y, Pankow J S, Duncan B B, Brancati F L. Vital capacity as a predictor of incident type 2 diabetes: the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 1472-1479. (Pubitemid 40756715)
22. Fogarty A W, Jones S, Britton J R, et al. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007; 62: 515-520. (Pubitemid 46910130)
23. Mahmud A, Feely J. Effect of smoking on arterial stiffness and pulse pressure amplification. Hypertension. 2003; 41: 183-187. (Pubitemid 36056812)
24. Li H, Srinivasan R S, Berenson G S. Comparison of measures of pulsatile arterial function between asymptomatic younger adult smokers and former smokers: the Bogalusa Heart Study. Am J Hypertens 2006; 19: 897-901. (Pubitemid 46106989)
25. Chobanian A V. 1989 Corcoran lecture: adaptive and maladaptive responses of the arterial wall to hypertension. Hypertension 1990; 15 (part 2): 666-674. (Pubitemid 20189440)
26. Barnes P J, Celli B R. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33: 1165-1185.
27. Sin D D, Man S F. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc 2005; 2: 8.
28. Paek Y J, Jung K S, Hwang Y I, et al. Association between low pulmonary function and metabolic risk factors in Korean adults: the Korean National Health and Nutrition Survey. Metabolism 2010; 59: 1300-1306.
29. Weiss N S, Rossing M A. Healthy screened bias in epidemiologic studies of cancer incidence. Epidemiology 1996; 7: 319-322. (Pubitemid 126448330)
30. Keddissi J I, Younis W G, Chbeir E A, Daher N N, Dernaika T A, Kinasewitz G T. The use of statins and lung function in current and former smokers. Chest 2007; 132: 1764-1771.
31. Alexeeff S E, Litonjua A A, Sparrow D, Vokonas P S, Schwartz J. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007; 176: 742-747. (Pubitemid 47598474)
32. Hsia C C, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118: 205-211. (Pubitemid 40312627)
33. Lazarus R, Gore C J, Booth M, Owen N. Effects of body composition and fat distribution on ventilatory function in adults. Am J Clin Nutr 1998; 68: 35- 41.
34. 1 in evaluation of COPD severity. COPD 2012; 9: 276-280.